Microfluidic Chip for Molecular Amplification of Influenza A RNA in Human Respiratory Specimens

DSpace/Manakin Repository

Microfluidic Chip for Molecular Amplification of Influenza A RNA in Human Respiratory Specimens

Citable link to this page

 

 
Title: Microfluidic Chip for Molecular Amplification of Influenza A RNA in Human Respiratory Specimens
Author: Cao, Qingqing; Mahalanabis, Madhumita; Chang, Jessie; Carey, Brendan; Hsieh, Christopher; Stanley, Ahjegannie; Odell, Christine A.; Mitchell, Patricia; Klapperich, Catherine M.; Pollock, Nira; Feldman, James

Note: Order does not necessarily reflect citation order of authors.

Citation: Cao, Qingqing, Madhumita Mahalanabis, Jessie Chang, Brendan Carey, Christopher Hsieh, Ahjegannie Stanley, Christine A. Odell, et al. 2012. Microfluidic chip for molecular amplification of influenza A RNA in human respiratory specimens. PLoS ONE 7(3): e33176.
Full Text & Related Files:
Abstract: A rapid, low cost, accurate point-of-care (POC) device to detect influenza virus is needed for effective treatment and control of both seasonal and pandemic strains. We developed a single-use microfluidic chip that integrates solid phase extraction (SPE) and molecular amplification via a reverse transcription polymerase chain reaction (RT-PCR) to amplify influenza virus type A RNA. We demonstrated the ability of the chip to amplify influenza A RNA in human nasopharyngeal aspirate (NPA) and nasopharyngeal swab (NPS) specimens collected at two clinical sites from 2008–2010. The microfluidic test was dramatically more sensitive than two currently used rapid immunoassays and had high specificity that was essentially equivalent to the rapid assays and direct fluorescent antigen (DFA) testing. We report 96% (CI 89%,99%) sensitivity and 100% (CI 95%,100%) specificity compared to conventional (bench top) RT-PCR based on the testing of n = 146 specimens (positive predictive value = 100%(CI 94%,100%) and negative predictive value = 96%(CI 88%,98%)). These results compare well with DFA performed on samples taken during the same time period (98% (CI 91%,100%) sensitivity and 96%(CI 86%,99%) specificity compared to our gold standard testing). Rapid immunoassay tests on samples taken during the enrollment period were less reliable (49%(CI 38%,61%) sensitivity and 98%(CI 98%,100%) specificity). The microfluidic test extracted and amplified influenza A RNA directly from clinical specimens with viral loads down to 103 copies/ml in 3 h or less. The new test represents a major improvement over viral culture in terms of turn around time, over rapid immunoassay tests in terms of sensitivity, and over bench top RT-PCR and DFA in terms of ease of use and portability.
Published Version: doi:10.1371/journal.pone.0033176
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3310856/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10318212
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters